G9888 Maintenance 5% wl from baseline weight in months 7-12
Billable / valid for submission HCPCS Release 2026Q3
Short description: 5% wl maintnd from bsline wt
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Maintenance 5% wl from baseline weight in months 7-12 | yes |
Related codes in G98
- G9805 Patients who use hospice services any time during the measurement period
- G9806 Patients who received cervical cytology or an hpv test
- G9807 Patients who did not receive cervical cytology or an hpv test
- G9812 Patient died including all deaths occurring during the hospitalization in which the operation was performed, even if after 30 days, and those deaths occurring after discharge from the hospital, but within 30 days of the procedure
- G9813 Patient did not die within 30 days of the procedure or during the index hospitalization
- G9818 Documentation of sexual activity
- G9819 Patients who use hospice services any time during the measurement period
- G9820 Documentation of a chlamydia screening test with proper follow-up
- G9821 No documentation of a chlamydia screening test with proper follow-up
- G9822 Patients who had an endometrial ablation procedure during the 12 months prior to the index date (exclusive of the index date)
- G9823 Endometrial sampling or hysteroscopy with biopsy and results documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation
- G9824 Endometrial sampling or hysteroscopy with biopsy and results not documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation
- G9830 Her-2/neu positive
- G9831 Ajcc stage at breast cancer diagnosis = ii or iii
- G9832 Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1c
- G9838 Patient has metastatic disease at diagnosis
- G9839 Anti-egfr monoclonal antibody therapy
- G9840 Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab
- G9841 Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab
- G9842 Patient has metastatic disease at diagnosis